These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177 [TBL] [Abstract][Full Text] [Related]
14. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection. Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2021; 12():824728. PubMed ID: 35154086 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. Launay O; Artaud C; Lachâtre M; Ait-Ahmed M; Klein J; Luong Nguyen LB; Durier C; Jansen B; Tomberger Y; Jolly N; Grossmann A; Tabbal H; Brunet J; Gransagne M; Choucha Z; Batalie D; Delgado A; Müllner M; Tschismarov R; Berghmans PJ; Martin A; Ramsauer K; Escriou N; Gerke C EBioMedicine; 2022 Jan; 75():103810. PubMed ID: 35045362 [TBL] [Abstract][Full Text] [Related]
16. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge. Wang G; Verma AK; Guan X; Bu F; Odle AE; Li F; Liu B; Perlman S; Du L J Virol; 2024 Sep; 98(9):e0037624. PubMed ID: 39189731 [TBL] [Abstract][Full Text] [Related]
17. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP Front Immunol; 2021; 12():781280. PubMed ID: 34987509 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299 [TBL] [Abstract][Full Text] [Related]
20. Development of an inactivated vaccine candidate for SARS-CoV-2. Gao Q; Bao L; Mao H; Wang L; Xu K; Yang M; Li Y; Zhu L; Wang N; Lv Z; Gao H; Ge X; Kan B; Hu Y; Liu J; Cai F; Jiang D; Yin Y; Qin C; Li J; Gong X; Lou X; Shi W; Wu D; Zhang H; Zhu L; Deng W; Li Y; Lu J; Li C; Wang X; Yin W; Zhang Y; Qin C Science; 2020 Jul; 369(6499):77-81. PubMed ID: 32376603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]